Identification
- Summary
Chikungunya vaccine (live, attenuated) is a live, attenuated vaccine used for the prevention of disease caused by chikungunya virus.
- Brand Names
- Ixchiq
- Generic Name
- Chikungunya vaccine (live, attenuated)
- DrugBank Accession Number
- DB18701
- Background
Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.1 It is spread primarily by the bite of infected mosquitos of the Aedes genus. Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia.1 Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.5 There are no approved treatments for active chikungunya virus infection.4
Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease caused by chikungunya virus.3 It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Chikungunya vaccine, live
- Chikungunya virus LR2006 OPY1 (attenuated strain) antigen
- External IDs
- VLA1553
Pharmacology
- Indication
Ixchiq (chikungunya vaccine, live) is indicated for the prevention of disease caused by chikungunya virus in patients ≥18 years of age who are at increased risk of exposure to chikungunya virus.2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Chikungunya virus infections •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Following intramuscular injection, viremia was not detected on day one and was detected in the greatest proportion of patients by day four.2 Viremia had resolved in all patients have day 15.2
- Mechanism of action
Intramuscular injection of live chikungunya virus (CHIKV) vaccine elicits CHIKV-specific immune responses.2
- Absorption
There is limited pharmacokinetic information on chikungunya virus vaccine.
- Volume of distribution
There is limited pharmacokinetic information on chikungunya virus vaccine.
- Protein binding
There is limited pharmacokinetic information on chikungunya virus vaccine.
- Metabolism
As with other live attenuated vaccines, chikungunya virus vaccine is likely to undergo nonspecific cellular degradation.
- Route of elimination
Although there is limited information on the main route of elimination of chikungunya virus vaccine, virus was detected in the urine of one participant on day 8 following intramuscular injection.2
- Half-life
There is limited pharmacokinetic information on chikungunya virus vaccine.
- Clearance
There is limited pharmacokinetic information on chikungunya virus vaccine.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
There are no data regarding overdosage of chikungunya virus vaccine.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Abatacept. Acyclovir The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Chikungunya vaccine (live, attenuated). Adefovir dipivoxil The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Adefovir dipivoxil. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Ixchiq (Valneva Austria GmbH)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ixchiq Injection, powder, lyophilized, for solution 3 [TCID_50]/0.5mL Intramuscular Valneva Scotland Ltd. 2024-01-15 Not applicable US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans
- Chikungunya virus
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, Herrero LJ, Zaid A, Ng LFP, Mahalingam S: Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017 Apr;17(4):e107-e117. doi: 10.1016/S1473-3099(16)30385-1. Epub 2017 Feb 1. [Article]
- FDA Approved Drug Products: Ixchiq (Chikungunya vaccine, live) solution for intramuscular injection [Link]
- FDA Press Announcement: FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus [Link]
- Centers for Disease Control & Prevention (CDC): Chikungunya Virus [Link]
- Centers for Disease Control & Prevention (CDC): Areas at Risk for Chikungunya [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Prevention Chikungunya Virus Infections 1 3 Completed Prevention Chikungunya Virus Infections 2 3 Not Yet Recruiting Prevention Chikungunya Virus Infections 1 2 Recruiting Prevention Chikungunya Virus Infections 1 1 Completed Prevention Chikungunya 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intramuscular 3 [TCID_50]/0.5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 20, 2023 20:58 / Updated at January 11, 2024 10:01